Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2007

01.08.2007 | Hepatic and Pancreatic Tumors

Analysis of Prognostic Factors Affecting Survival After Initial Recurrence and Treatment Efficacy for Recurrence in Patients Undergoing Potentially Curative Hepatectomy for Hepatocellular Carcinoma

verfasst von: Kazuaki Shimada, MD, Yoshihiro Sakamoto, MD, Minoru Esaki, MD, Tomoo Kosuge, MD, Chigusa Morizane, MD, Masafumi Ikeda, MD, Hideki Ueno, MD, Takuji Okusaka, MD, Yasuaki Arai, MD, Kenichi Takayasu, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Survival analysis in patients with initial recurrence after curative hepatectomy for hepatocellular carcinoma (HCC) has not been well evaluated. In addition, selections of the most effective treatments for patients with recurrent HCC still remain controversial.

Methods

Three hundred and nineteen patients who underwent potentially curative hepatectomies were followed for initial recurrence, and factors predictive of recurrence were determined. The factors affecting survival including pattern of recurrence and treatment modalities from the time of initial recurrence in 211 patients were retrospectively analyzed.

Results

The overall 5-year disease-free survival rate of 319 patients was 31.1%. The 5-year survival rate of 211 patients from the time of initial recurrence was 31.9%. In a multivariate analysis, a low indocyanine green retention rate, lack of liver cirrhosis, a long interval before recurrence, the absence of portal vein invasion, and intrahepatic recurrence (≤3 nodules) were shown to be significantly favorable prognostic factors after the initial recurrence. The 5-year survival rate of patients with intrahepatic recurrence (≤3 nodules) was 42.3%, and no survival differences were observed among different treatment modalities.

Conclusion

When the initial recurrence occurred after a longer interval, and/or with three or fewer intrahepatic recurrent nodules, a favorable prognosis could be expected in those patients with better liver function and no portal vein invasion at the time of the primary hepatectomy. It is important to conduct a randomized controlled trial to clarify a method for selecting optimal treatment in patients with a smaller number of initial intrahepatic recurrences.
Literatur
1.
Zurück zum Zitat Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000; 191:38–46PubMedCrossRef Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000; 191:38–46PubMedCrossRef
2.
Zurück zum Zitat Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002; 236:397–406PubMedCrossRef Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002; 236:397–406PubMedCrossRef
3.
Zurück zum Zitat Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003; 138:1198–206PubMedCrossRef Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003; 138:1198–206PubMedCrossRef
4.
Zurück zum Zitat Takenaka K, Adachi E, Nishizaki T, et al. Possible multicentric occurrence of hepatocellular carcinoma: a clinicopathological study. Hepatology 1994; 19:889–94PubMedCrossRef Takenaka K, Adachi E, Nishizaki T, et al. Possible multicentric occurrence of hepatocellular carcinoma: a clinicopathological study. Hepatology 1994; 19:889–94PubMedCrossRef
5.
Zurück zum Zitat Funaki NO, Tanaka J, Seto S, et al. Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver. Hepatology 1997; 25:564–8PubMedCrossRef Funaki NO, Tanaka J, Seto S, et al. Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver. Hepatology 1997; 25:564–8PubMedCrossRef
7.
Zurück zum Zitat Takayasu K, Furukawa H, Wakao F, et al. CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. Am J Roentgenol 1995; 164:885–90 Takayasu K, Furukawa H, Wakao F, et al. CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. Am J Roentgenol 1995; 164:885–90
8.
Zurück zum Zitat Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998; 28:1241–6PubMedCrossRef Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998; 28:1241–6PubMedCrossRef
9.
Zurück zum Zitat Nakajima Y, Ohmura T, Kimura J, et al. Role of surgical treatment for recurrent hepatocellular carcinoma after hepatic resection. World J Surg 1993; 17:792–5PubMedCrossRef Nakajima Y, Ohmura T, Kimura J, et al. Role of surgical treatment for recurrent hepatocellular carcinoma after hepatic resection. World J Surg 1993; 17:792–5PubMedCrossRef
10.
Zurück zum Zitat Suenaga M, Sugiura H, Kokuba Y, et al. Repeated hepatic resection for recurrent hepatocellular carcinoma in eighteen cases. Surgery 1994; 115:452–7PubMed Suenaga M, Sugiura H, Kokuba Y, et al. Repeated hepatic resection for recurrent hepatocellular carcinoma in eighteen cases. Surgery 1994; 115:452–7PubMed
11.
Zurück zum Zitat Hu RH, Lee PH, Yu SC, et al. Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. Surgery 1996; 120:23–29PubMedCrossRef Hu RH, Lee PH, Yu SC, et al. Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. Surgery 1996; 120:23–29PubMedCrossRef
12.
Zurück zum Zitat Shimada M, Takenaka K, Taguchi K, et al. Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg 1998; 227:80–5PubMedCrossRef Shimada M, Takenaka K, Taguchi K, et al. Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg 1998; 227:80–5PubMedCrossRef
13.
Zurück zum Zitat Poon RTP, Fan ST, Lo CM, et al. Intrahepatic recurrence after curative recurrence of hepatocellular carcinoma: Long-term results of treatment and prognostic factors. Ann Surg 1999; 229:216–22PubMedCrossRef Poon RTP, Fan ST, Lo CM, et al. Intrahepatic recurrence after curative recurrence of hepatocellular carcinoma: Long-term results of treatment and prognostic factors. Ann Surg 1999; 229:216–22PubMedCrossRef
14.
Zurück zum Zitat Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 2003; 238:703–10PubMedCrossRef Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 2003; 238:703–10PubMedCrossRef
15.
Zurück zum Zitat Yamamoto J, Okada S, Shimada K, et al. Treatment strategy for small hepatocellular carcinoma: Comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001; 34:707–13PubMedCrossRef Yamamoto J, Okada S, Shimada K, et al. Treatment strategy for small hepatocellular carcinoma: Comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001; 34:707–13PubMedCrossRef
16.
Zurück zum Zitat Taura K, Ikai I, Hatano E, Fujii H, Uyama N, Shimaharu Y. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection An analysis of 610 patients over 16 years old. Ann Surg 2006; 244:265–73PubMedCrossRef Taura K, Ikai I, Hatano E, Fujii H, Uyama N, Shimaharu Y. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection An analysis of 610 patients over 16 years old. Ann Surg 2006; 244:265–73PubMedCrossRef
17.
Zurück zum Zitat Lee PH, Lin WJ, Tsang YM, et al. Clinical management of recurrent hepatocellular carcinoma. Ann Surg 1995; 222:670–6PubMedCrossRef Lee PH, Lin WJ, Tsang YM, et al. Clinical management of recurrent hepatocellular carcinoma. Ann Surg 1995; 222:670–6PubMedCrossRef
18.
Zurück zum Zitat Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131:461–9PubMedCrossRef Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131:461–9PubMedCrossRef
19.
Zurück zum Zitat Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1996; 334:693–9PubMedCrossRef Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1996; 334:693–9PubMedCrossRef
20.
Zurück zum Zitat Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma Experience in Japan. Ann Surg 2004; 240:451–61PubMedCrossRef Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma Experience in Japan. Ann Surg 2004; 240:451–61PubMedCrossRef
21.
Zurück zum Zitat Arii S, Tanaka J, Yamazoe Y, et al. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer 1991; 69:913–9CrossRef Arii S, Tanaka J, Yamazoe Y, et al. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer 1991; 69:913–9CrossRef
22.
Zurück zum Zitat Nagasue N, Uchida M, Makino Y, et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993; 105:488–94PubMed Nagasue N, Uchida M, Makino Y, et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993; 105:488–94PubMed
23.
Zurück zum Zitat Okada S, Shimada K, Yamamoto J, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994; 106:1618–24PubMed Okada S, Shimada K, Yamamoto J, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994; 106:1618–24PubMed
24.
Zurück zum Zitat Poon RTP, Ng IO, Fan ST, et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: A study of a prospective cohort. J Clin Oncol 2001; 19:3037–44PubMed Poon RTP, Ng IO, Fan ST, et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: A study of a prospective cohort. J Clin Oncol 2001; 19:3037–44PubMed
25.
Zurück zum Zitat Portolani N, Coniglio A, Giovanelli M, et al. Early and late recurrence after resection for hepatocellular carcinoma Prognosis and therapeutic implications. Ann Surg 2006 243:229–35PubMedCrossRef Portolani N, Coniglio A, Giovanelli M, et al. Early and late recurrence after resection for hepatocellular carcinoma Prognosis and therapeutic implications. Ann Surg 2006 243:229–35PubMedCrossRef
26.
Zurück zum Zitat Shimada M, Takenaka K, Gion T, et al. Prognosis of recurrent hepatocellular carcinoma: A 10-year surgical experience in Japan. Gastroenterology 1996; 111:720–6PubMedCrossRef Shimada M, Takenaka K, Gion T, et al. Prognosis of recurrent hepatocellular carcinoma: A 10-year surgical experience in Japan. Gastroenterology 1996; 111:720–6PubMedCrossRef
27.
Zurück zum Zitat Miyagawa M, Makuuchi M, Kawasaki S, et al. Criteria for safe hepatic resection. Am J Surg 1995; 169:589–94PubMedCrossRef Miyagawa M, Makuuchi M, Kawasaki S, et al. Criteria for safe hepatic resection. Am J Surg 1995; 169:589–94PubMedCrossRef
28.
Zurück zum Zitat Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 2nd ed. Tokyo: Kanehara, 2003 Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 2nd ed. Tokyo: Kanehara, 2003
29.
Zurück zum Zitat Yamanaka N, Tanaka T, Tanaka W, et al. Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer 1997; 79:1509–15PubMedCrossRef Yamanaka N, Tanaka T, Tanaka W, et al. Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer 1997; 79:1509–15PubMedCrossRef
30.
Zurück zum Zitat Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138:299–306PubMed Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138:299–306PubMed
31.
Zurück zum Zitat Park JH, Koh KC, Choi MS, et al. Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. Am J Surg 2006; 192:29–33PubMedCrossRef Park JH, Koh KC, Choi MS, et al. Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. Am J Surg 2006; 192:29–33PubMedCrossRef
32.
Zurück zum Zitat Sakon M, Nagano H, Dono K, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94:435–42PubMedCrossRef Sakon M, Nagano H, Dono K, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94:435–42PubMedCrossRef
33.
Zurück zum Zitat Ando E, Tanaka M, Yamashita F. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95:588–95PubMedCrossRef Ando E, Tanaka M, Yamashita F. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95:588–95PubMedCrossRef
34.
Zurück zum Zitat Ryu M, Shimamura Y, Kinoshita T, et al. Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a prospective multicenter study. Jpn J Clin Oncol 1997; 27:251–7PubMedCrossRef Ryu M, Shimamura Y, Kinoshita T, et al. Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a prospective multicenter study. Jpn J Clin Oncol 1997; 27:251–7PubMedCrossRef
35.
Zurück zum Zitat Matsui O, Kadoya N, Yoshikawa J, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993; 188:79–83PubMed Matsui O, Kadoya N, Yoshikawa J, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993; 188:79–83PubMed
36.
Zurück zum Zitat Takayasu K, Muramatsu Y, Maeda T, et al. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. Am J Roentgenol 2001; 176:681–8 Takayasu K, Muramatsu Y, Maeda T, et al. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. Am J Roentgenol 2001; 176:681–8
37.
Zurück zum Zitat Lau WY, Leung TWT, Yu SCH, Ho SKW. Percutaneous local ablate therapy for hepatocellular carcinoma A review and look into the future. Ann Surg 2003; 2:171–9CrossRef Lau WY, Leung TWT, Yu SCH, Ho SKW. Percutaneous local ablate therapy for hepatocellular carcinoma A review and look into the future. Ann Surg 2003; 2:171–9CrossRef
38.
Zurück zum Zitat Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial. Lancet 1999; 353:797–801PubMedCrossRef Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial. Lancet 1999; 353:797–801PubMedCrossRef
Metadaten
Titel
Analysis of Prognostic Factors Affecting Survival After Initial Recurrence and Treatment Efficacy for Recurrence in Patients Undergoing Potentially Curative Hepatectomy for Hepatocellular Carcinoma
verfasst von
Kazuaki Shimada, MD
Yoshihiro Sakamoto, MD
Minoru Esaki, MD
Tomoo Kosuge, MD
Chigusa Morizane, MD
Masafumi Ikeda, MD
Hideki Ueno, MD
Takuji Okusaka, MD
Yasuaki Arai, MD
Kenichi Takayasu, MD
Publikationsdatum
01.08.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9415-7

Weitere Artikel der Ausgabe 8/2007

Annals of Surgical Oncology 8/2007 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.